Zimlovisertib

Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas[1][2].

Product Specifications

CAS Number

[1817626-54-2]

Product Name Alternative

PF-06650833

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

IRAK

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/PF06650833.html

Purity

99.94

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC(C1=C(OC)C=C2C(C=CN=C2OC[C@@H]3[C@H](CC)[C@H](F)C(N3)=O)=C1)=O

Molecular Formula

C18H20FN3O4

Molecular Weight

361.37

Precautions

H315, H319, H335

References & Citations

[1]Seganish WM. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) : a patent review (2012-2015) . Expert Opin Ther Pat. 2016 Aug;26 (8) :917-32.|[2]Lee KL, et al. Discovery of Clinical Candidate 1-{[ (2S,3S,4S) -3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017 Jul 13;60 (13) :5521-5542.